Skip to main
PODD

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 50%
Hold 0%
Sell 6%
Strong Sell 0%

Bulls say

Insulet Corporation has demonstrated significant financial growth, achieving record new customer starts in the fourth quarter of 2025, with a year-over-year revenue increase of 31% to reach $784 million. This growth can be attributed to strong volume growth, improved manufacturing productivity at its facilities in Acton and Malaysia, as well as favorable pricing dynamics stemming from international customers transitioning to the Omnipod 5 system. Additionally, the company continues to strategically invest in its manufacturing capabilities, with capital expenditures growing to $135 million in the fourth quarter, laying a solid foundation for future expansion and operational efficiency.

Bears say

Insulet's stock faces a negative outlook primarily due to heightened competition within the insulin delivery market, contributing to a significant decline in drug delivery revenues, which were reported down approximately 50%. Additionally, despite respectable US Omnipod growth estimates of 20-22% and international growth of 27-29%, broader market trends driven by poor sentiment, particularly in obesity-related therapeutic areas, have seen peers trading well below historical averages. Furthermore, there are concerns regarding pipeline product approval delays, which may hinder future growth potential for the company.

Insulet (PODD) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 18 analysts, Insulet (PODD) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $354.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $354.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.